Xintela and NorthX Biologics announced they have signed a collaboration framework agreement to facilitate projects of common interest utilizing their complementary resources and competences in developing and manufacturing Advanced Therapy Medicinal Products (ATMPs). Projects to be initiated under the collaboration framework include product and process development, quality management and expansion capacity for manufacturing ATMPs, among other things.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.27 SEK | +0.75% | -10.00% | -0.37% |
May. 24 | Xintela AB Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
May. 23 | Xintela and EQGen Biomedical to Collaborate to Develop EQSTEM Stem Cell Treatment for Horses | CI |
1st Jan change | Capi. | |
---|---|---|
-0.37% | 14.47M | |
+18.97% | 44.44B | |
+41.98% | 40.03B | |
-10.06% | 37.68B | |
+31.15% | 31.46B | |
-7.79% | 27.29B | |
+13.32% | 26.29B | |
+43.05% | 13.8B | |
+31.28% | 12.46B | |
-7.41% | 11.26B |
- Stock Market
- Equities
- XINT Stock
- News Xintela AB
- Xintela and Northx Biologics Sign Collaboration Framework Agreement